CRDL Share Price Performance
CA$1.47
-0.46 (-23.83%)
Price CA$1.47
Share Pricen/a
Analysis Article • Jun 04
Cardiol Therapeutics Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
CRDL Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Cardiol Therapeutics Inc. Key Details
About CRDL
- Founded
- 2017
- Employees
- 18
- CEO
- WebsiteView website
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
